Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy.

Item

http://www.wikidata.org/entity/Q38285627

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy.

@en

type

Item

label

Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy.

@en

prefLabel

Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy.

@en

P1476

Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy.

@en

P2093

Hirokazu Nagai

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

P304

137-145

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JJCO/HYU204

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269414259

http://www.w3.org/2001/XMLSchema#string

P698

25489004

http://www.w3.org/2001/XMLSchema#string